A group led by scientists at Danderyd Hospital, a part of the Karolinska Institute in Stockholm, carried out the research from April 2020 to January 2021. The analysis concerned acquiring blood samples and administering questionnaires to healthcare workers taking part within the ongoing COVID-19 Biomarker and Immunity (COMMUNITY) research.
Symptoms for no less than 2 months in 26%
Of the 323 individuals who have been seropositive, or had antibodies in opposition to SARS-CoV-2, indicating earlier an infection, 26% reported no less than one reasonable to extreme symptom persisting for no less than 2 months, in contrast with 9% of 1,072 seronegative individuals (threat ratio [RR], 2.9). Similarly, 15% of seropositive and three% of seronegative individuals mentioned that they had a lingering symptom for 8 months or extra (RR, 4.4).
Among the seropositive individuals, 8% mentioned that their lingering signs brought on reasonable to marked disruptions of their work life, in contrast with 4% of the seronegative group (RR, 1.8).
Likewise, 15% of seropositive individuals mentioned their persistent signs disrupted their social life to a reasonable to marked diploma, in contrast with 6% of the seronegative group (RR, 2.5). And 12% of the seropositive group reported disruptions to their residence life, versus 5% of the seronegative group (RR, 2.3).
In addition to reporting no less than one symptom lasting 8 months or longer, 11% of seropositive individuals indicated a reasonable to marked disruption in any class of the Sheehan Disability Scale, in contrast with 2% of the seronegative group (RR, 4.5).
Lower long-term high quality of life
The most typical signs lasting for no less than 2 months within the seropositive group included fatigue, lack of odor or style, and shortness of breath.
“However, we do not see an increased prevalence of cognitive symptoms such as brain fatigue, memory and concentration problems or physical disorders such as muscle and joint pain, heart palpitations or long-term fever,” senior writer Charlotte Thalin, MD, PhD, mentioned in a Karolinska Institute news release.
Seropositive group members who mentioned that they had no or mild earlier signs had a median age of 43 years, and 83% have been ladies, whereas median age within the seronegative group was 47 years, and 86% have been ladies.
Among seropositive individuals, 22% reported having persistent underlying circumstances, in contrast with 24% of the seronegative group.
“The results of this study showed that a considerable portion of low-risk individuals with mild COVID-19 reported a diversity of long-term symptoms, and that these symptoms disrupted work, social, and home life,” the authors wrote. “Further research is needed to understand the mechanisms underlying COVID-19–related long-term sequalae.”
Lead writer Sebastian Havervall, MD, mentioned within the launch that the findings illustrate the intense long-term penalties of COVID-19 after even mild illness. “Despite the fact that the study participants had a mild COVID-19 infection, a relatively large proportion report long-term symptoms with an impact on quality of life,” he mentioned.
“In light of this, we believe that young and healthy individuals, as well as other groups in society, should have great respect for the virus that seems to be able to significantly impair quality of life, even for a long time after the infection.”